Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorYapislar, Hande
dc.contributor.authorHaciosmanoglu, Ebru
dc.contributor.authorSarioglu, Turkan
dc.contributor.authorDegirmencioglu, Sevgin
dc.contributor.authorSogut, Ibrahim
dc.contributor.authorPoteser, Michael
dc.contributor.authorEkmekcioglu, Cem
dc.date.accessioned2022-12-05T09:45:24Z
dc.date.available2022-12-05T09:45:24Z
dc.date.issued2022en_US
dc.identifier.citationYapislar, H., Haciosmanoglu, E., Sarioglu, T., Degirmencioglu, S., Sogut, I., Poteser, M., & Ekmekcioglu, C. (2022). Anti-Inflammatory Effects of Melatonin in Rats with Induced Type 2 Diabetes Mellitus. Life, 12(4), 574.en_US
dc.identifier.issn2075-1729
dc.identifier.urihttps://doi.org/10.3390/life12040574
dc.identifier.urihttps://hdl.handle.net/20.500.12294/3075
dc.description.abstractIntroduction: Insulin resistance is associated with a pro-inflammatory state increasing the risk for complications in patients with type 2 diabetes mellitus (T2DM). In addition to its chronobi-otic effects, the pineal hormone melatonin is known to exert anti-inflammatory and antioxidant ef-fects. Melatonin was also suggested to affect insulin secretion. The aim of this study was therefore to investigate the effect of melatonin on inflammation in diabetic rats and to study the possible involvement of the melatonin receptor, MT2. Materials and Methods: Male Sprague Dawley rats were randomly divided into four experimental groups (n = 10 per group): (1) control, (2) strepto-zotocin/nicotinamide induced diabetes type 2 (T2DM), (3) T2DM treated with melatonin (500 µg/kg/day), and (4) T2DM treated with melatonin (500 µg/kg/day for 6 weeks) and the selective MT2 receptor antagonist luzindole (0.25 g/kg/day for 6 weeks). Blood samples were taken for biochemical parameters and various tissue samples (liver, adipose tissue, brain) were removed for im-munohistochemistry (IHC), Western blot (WB), and Q-PCR analyses, respectively. Results: Melato-nin significantly reduced increased blood levels of liver transaminases (AST, ALT), blood urea ni-trogen (BUN), triglyceride, very low-density lipoprotein (VLDL), and cholesterol in diabetic rats with luzindole treatment partly reversing this effect regarding the lipids. Furthermore, the liver and adipose tissues of T2DM rats treated with melatonin showed lower expression of the inflammatory markers IL-1β, IL-6, TNF-α, and NF-κB as compared to the T2DM group without melatonin. The results also showed that the MT2 receptor is at least partly involved in the protective effects of mel-atonin. Conclusions: Our results suggest that melatonin exerts relevant anti-inflammatory effects on various tissues in type 2 diabetic rats. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.en_US
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.relation.ispartofLifeen_US
dc.identifier.doi10.3390/life12040574en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectExperimental Diabetes Mellitusen_US
dc.subjectInflammationen_US
dc.subjectMelatoninen_US
dc.subjectMT2en_US
dc.subjectType 2 Diabetes Mellitusen_US
dc.titleAnti-Inflammatory Effects of Melatonin in Rats with Induced Type 2 Diabetes Mellitusen_US
dc.typearticleen_US
dc.departmentTıp Fakültesi, Temel Tıp Bilimlerien_US
dc.authorid0000-0001-7243-3671en_US
dc.identifier.volume12en_US
dc.identifier.issue4en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.institutionauthorDegirmencioglu, Sevgin
dc.authorwosidM-4010-2017en_US
dc.authorscopusid25632114400en_US
dc.identifier.wosqualityQ2en_US
dc.identifier.wosWOS:000786783500001en_US
dc.identifier.scopus2-s2.0-85128991847en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster